Potential effects: nausea, constipation
Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis
No serious clinician disputes the numbers
Studies have shown people losing 5% of their body weight and newer studies have shown people losing up to 10% of their body weight
Gastrointestinal side effects are the most common and include: Nausea (reported in 12% to 29% of patients, depending on dose) Diarrhea (occurring in 13% to 23% of patients) Vomiting (affecting 4% to 9% of patients) Constipation (reported in 6% to 11% of patients) Abdominal pain and dyspepsia (affecting 6% to 9% of patients) Decreased appetite (common and often contributes to weight loss) These gastrointestinal symptoms typically occur during dose escalation and often improve with continued use
Conquering the Queasiness: How to Handle Nausea on Your GLP-1 Journey If you are taking a GLP-1 (like semaglutide) or a GLP-1/GIP (like tirzepatide) medication, you might be experiencing a "love-hate" relationship: you love the weight loss results, but you hate the occasional wave of nausea